Megha Bhumralkar's practice focuses on United States and foreign patent prosecution in the areas of biotechnology, chemistry, and pharmaceuticals. In addition, Megha is involved in preparation of noninfringement, invalidity, and freedom-to-operate opinions.
Before joining Jones Day, Megha was a technology specialist at the San Diego offices of Fish & Richardson and Hellar Ehrman. Prior to entering the intellectual property field, she was a postdoctoral research fellow at the University of California, San Diego where her research involved synthetic collagen mimetics. She worked extensively on small molecule heterocycles during her graduate studies.
Megha is a member of the American Chemical Society and the San Diego Intellectual Property Law Association.
MEI Pharma develops patent portfolio for small molecule PI3K delta inhibitors
Jones Day represents MEI Pharma, Inc. in patent prosecution of small molecule PI3K delta inhibitors.
Ambit Biosciences develops patent portfolio for small molecule kinase inhibitor programs
Jones Day represented Ambit Biosciences in the development of patent portfolios related to small molecule kinase inhibitor programs and phage-displayed protein assays.
Sunesis Pharmaceuticals builds patent portfolio for small molecule oncological drugs
Jones Day assisted Sunesis Pharmaceuticals, Inc. with the patent prosecution and portfolio management relating to small molecule oncological drugs.
- Nagpur University, India (Ph.D. in Organic Chemistry 1997; M.Sc. in Chemistry 1990; B.Sc. in Chemistry 1988)
- Registered to practice before the United States Patent and Trademark Office